These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Spironolactone and risk of upper gastrointestinal events: population based case-control study. Verhamme K; Mosis G; Dieleman J; Stricker B; Sturkenboom M BMJ; 2006 Aug; 333(7563):330. PubMed ID: 16840442 [TBL] [Abstract][Full Text] [Related]
46. Spironolactone and risk of upper gastrointestinal events: spironolactone may not be guilty. Campbell E; Shonde A; Foley S BMJ; 2006 Sep; 333(7566):500; author reply 500-1. PubMed ID: 16946346 [No Abstract] [Full Text] [Related]
47. Use of spironolactone in dermatology. Rathnayake D; Sinclair R Skinmed; 2010; 8(6):328-32; quiz 333. PubMed ID: 21413648 [TBL] [Abstract][Full Text] [Related]
48. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia. Cruz CS; Cruz LS; Domingues GS; Souza CA Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447 [TBL] [Abstract][Full Text] [Related]
49. Understanding the risk of hyperkalaemia in heart failure: role of aldosterone antagonism. Poggio R; Grancelli HO; Miriuka SG Postgrad Med J; 2010 Mar; 86(1013):136-42. PubMed ID: 20237007 [TBL] [Abstract][Full Text] [Related]
50. Spironolactone management of resistant hypertension. Marrs JC Ann Pharmacother; 2010 Nov; 44(11):1762-9. PubMed ID: 20978214 [TBL] [Abstract][Full Text] [Related]